These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25406994)

  • 41. Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients.
    Partipilo G; Simone G; Scattone A; Scarpi E; Azzariti A; Mangia A
    Int J Cancer; 2016 Jan; 138(1):110-20. PubMed ID: 26205471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer.
    Johansson I; Nilsson C; Berglund P; Strand C; Jönsson G; Staaf J; Ringnér M; Nevanlinna H; Barkardottir RB; Borg A; Olsson H; Luts L; Fjällskog ML; Hedenfalk I
    Breast Cancer Res Treat; 2011 Oct; 129(3):747-60. PubMed ID: 21113657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification and pathway analysis of microRNAs with no previous involvement in breast cancer.
    Romero-Cordoba S; Rodriguez-Cuevas S; Rebollar-Vega R; Quintanar-Jurado V; Maffuz-Aziz A; Jimenez-Sanchez G; Bautista-Piña V; Arellano-Llamas R; Hidalgo-Miranda A
    PLoS One; 2012; 7(3):e31904. PubMed ID: 22438871
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genome methylation patterns in male breast cancer - Identification of an epitype with hypermethylation of polycomb target genes.
    Johansson I; Lauss M; Holm K; Staaf J; Nilsson C; Fjällskog ML; Ringnér M; Hedenfalk I
    Mol Oncol; 2015 Oct; 9(8):1565-79. PubMed ID: 25990542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. miRNA expression profiling of formalin-fixed paraffin-embedded (FFPE) hereditary breast tumors.
    Tanić M; Yanowski K; Andrés E; Gómez-López G; Socorro MR; Pisano DG; Martinez-Delgado B; Benítez J
    Genom Data; 2015 Mar; 3():75-9. PubMed ID: 26484152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Familial breast cancer and genes involved in breast carcinogenesis.
    Lindblom A
    Breast Cancer Res Treat; 1995 May; 34(2):171-83. PubMed ID: 7647334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility.
    Piccolo SR; Hoffman LM; Conner T; Shrestha G; Cohen AL; Marks JR; Neumayer LA; Agarwal CA; Beckerle MC; Andrulis IL; Spira AE; Moos PJ; Buys SS; Johnson WE; Bild AH
    Mol Syst Biol; 2016 Mar; 12(3):860. PubMed ID: 26969729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. miRNA deregulation and relationship with metabolic parameters after Mediterranean dietary intervention in BRCA-mutated women.
    De Summa S; Traversa D; Daniele A; Palumbo O; Carella M; Stallone R; Tufaro A; Oliverio A; Bruno E; Digennaro M; Danza K; Pasanisi P; Tommasi S
    Front Oncol; 2023; 13():1147190. PubMed ID: 37081976
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining.
    Nanayakkara J; Tyryshkin K; Yang X; Wong JJM; Vanderbeck K; Ginter PS; Scognamiglio T; Chen YT; Panarelli N; Cheung NK; Dijk F; Ben-Dov IZ; Kim MK; Singh S; Morozov P; Max KEA; Tuschl T; Renwick N
    NAR Cancer; 2020 Sep; 2(3):zcaa009. PubMed ID: 32743554
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrative clustering of high-dimensional data with joint and individual clusters.
    Hellton KH; Thoresen M
    Biostatistics; 2016 Jul; 17(3):537-48. PubMed ID: 26917056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
    Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.
    Minami A; Nakanishi A; Ogura Y; Kitagishi Y; Matsuda S
    Front Oncol; 2014; 4():318. PubMed ID: 25426449
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.
    Fumagalli D; Blanchet-Cohen A; Brown D; Desmedt C; Gacquer D; Michiels S; Rothé F; Majjaj S; Salgado R; Larsimont D; Ignatiadis M; Maetens M; Piccart M; Detours V; Sotiriou C; Haibe-Kains B
    BMC Genomics; 2014 Nov; 15(1):1008. PubMed ID: 25412710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review.
    Bernier J; Poortmans P
    Breast; 2015 Apr; 24(2):100-6. PubMed ID: 25557581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
    Gu Y; Zhang M; Peng F; Fang L; Zhang Y; Liang H; Zhou W; Ao L; Guo Z
    Oncotarget; 2015 Feb; 6(4):2397-406. PubMed ID: 25537514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
    Nicum S; Roberts C; Boyle L; Kopijasz S; Gourley C; Hall M; Montes A; Poole C; Collins L; Schuh A; Dutton SJ;
    BMC Cancer; 2014 Dec; 14():983. PubMed ID: 25526776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic testing for RAD51C mutations: in the clinic and community.
    Sopik V; Akbari MR; Narod SA
    Clin Genet; 2015 Oct; 88(4):303-12. PubMed ID: 25470109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mining cancer gene expression databases for latent information on intronic microRNAs.
    Monterisi S; D'Ario G; Dama E; Rotmensz N; Confalonieri S; Tordonato C; Troglio F; Bertalot G; Maisonneuve P; Viale G; Nicassio F; Vecchi M; Di Fiore PP; Bianchi F
    Mol Oncol; 2015 Feb; 9(2):473-87. PubMed ID: 25459350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer.
    Gökmen-Polar Y; Neelamraju Y; Goswami CP; Gu X; Nallamothu G; Janga SC; Badve S
    Mod Pathol; 2015 May; 28(5):677-85. PubMed ID: 25431237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.